NASDAQ:CDXS Codexis Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.00 +1.12 (+10.29%) (As of 07/5/2022 05:45 PM ET) Add Compare Share Today's Range$10.55▼$12.0250-Day Range$8.35▼$12.8252-Week Range$8.11▼$42.01Volume634,321 shsAverage Volume746,541 shsMarket Capitalization$783.60 millionP/E RatioN/ADividend YieldN/APrice Target$35.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Codexis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside193.8% Upside$35.25 Price TargetShort InterestHealthy8.30% of Float Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$396,935 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.72 out of 5 starsMedical Sector666th out of 1,426 stocksIndustrial Organic Chemicals Industry15th out of 25 stocks 3.5 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.25, Codexis has a forecasted upside of 193.8% from its current price of $12.00.Amount of Analyst CoverageCodexis has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.30% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Codexis has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 1.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 1.5 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Codexis this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $396,935.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Codexis is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.41) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -36.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -36.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address About Codexis (NASDAQ:CDXS) StockCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More CDXS Stock News HeadlinesJune 27, 2022 | finance.yahoo.comCodexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?June 27, 2022 | finance.yahoo.comThe 26% return this week takes Codexis' (NASDAQ:CDXS) shareholders five-year gains to 110%July 6, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 25, 2022 | businesswire.comGlobal Enzymes Market Report to 2031 - by Product Type, Source, Reaction Type, Application and Region - ResearchAndMarkets.com - Business WireJune 22, 2022 | americanbankingnews.comCodexis, Inc. (NASDAQ:CDXS) Receives $35.25 Average PT from BrokeragesJune 19, 2022 | americanbankingnews.comCodexis (NASDAQ:CDXS) Stock Price Up 8.4%June 18, 2022 | finance.yahoo.comCodexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides - Yahoo FinanceJune 17, 2022 | globenewswire.comCodexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides - GlobeNewswireJuly 6, 2022 | Investing Trends (Ad)Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022If you missed the boat on Tesla stocks, it's not too late! But don't follow the crowd and think EV makers are the most exciting investment. The smart money is focused on the miners that supply battery-grade lithium to EV manufacturers. With lithium demand expected to increase 10x by 2030, this industry is set to explode...June 17, 2022 | finance.yahoo.comCodexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native PeptidesJune 15, 2022 | americanbankingnews.comCodexis (NASDAQ:CDXS) Sets New 12-Month Low at $8.68May 19, 2022 | globenewswire.comGlobal Synthetic Biology Market to Surpass US$ 100.4 Billion by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireMay 18, 2022 | finance.yahoo.comCodexis to Participate in Upcoming Healthcare Conferences - Yahoo FinanceMay 17, 2022 | globenewswire.comCodexis to Participate in Upcoming Healthcare Conferences - GlobeNewswireMay 17, 2022 | finance.yahoo.comCodexis to Participate in Upcoming Healthcare ConferencesMay 16, 2022 | globenewswire.comCodexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting - GlobeNewswireMay 16, 2022 | finance.yahoo.comCodexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual MeetingMay 12, 2022 | finance.yahoo.comIs It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?May 11, 2022 | benzinga.comStephens & Co. Maintains Overweight on Codexis, Lowers Price Target to $22 - Benzinga - BenzingaMay 6, 2022 | streetinsider.comCodexis Reports First Quarter 2022 Financial Results - StreetInsider.comMay 5, 2022 | apnews.comCodexis: Q1 Earnings Snapshot - The Associated Press - en EspañolMay 4, 2022 | seekingalpha.comCodexis Q1 2022 Earnings Preview (NASDAQ:CDXS) - Seeking AlphaMay 2, 2022 | globenewswire.comCodexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting - GlobeNewswireMay 2, 2022 | finance.yahoo.comCodexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual MeetingApril 28, 2022 | nasdaq.comAnalysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for - NasdaqApril 28, 2022 | finance.yahoo.comAnalysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out forApril 27, 2022 | nasdaq.comAfter Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS) - NasdaqSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Industrial organic chemicals Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees261Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$35.25 High Stock Price Forecast$39.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+193.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,280,000.00 Net Margins-16.85% Pretax Margin-16.69% Return on Equity-12.56% Return on Assets-8.93% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.86 Sales & Book Value Annual Sales$104.75 million Price / Sales7.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.53 per share Price / Book4.74Miscellaneous Outstanding Shares65,300,000Free Float60,733,000Market Cap$783.60 million OptionableOptionable Beta1.90 Codexis Frequently Asked Questions Should I buy or sell Codexis stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock. View analyst ratings for Codexis or view top-rated stocks. What is Codexis' stock price forecast for 2022? 4 brokerages have issued 12-month price objectives for Codexis' stock. Their CDXS stock forecasts range from $30.00 to $39.00. On average, they anticipate Codexis' stock price to reach $35.25 in the next year. This suggests a possible upside of 193.8% from the stock's current price. View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts. How has Codexis' stock performed in 2022? Codexis' stock was trading at $31.27 at the beginning of the year. Since then, CDXS shares have decreased by 61.6% and is now trading at $12.00. View the best growth stocks for 2022 here. When is Codexis' next earnings date? Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Codexis. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The biotechnology company had revenue of $35.34 million for the quarter, compared to analysts' expectations of $28.58 million. Codexis had a negative trailing twelve-month return on equity of 12.56% and a negative net margin of 16.85%. The business's revenue for the quarter was up 96.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. View Codexis' earnings history. What guidance has Codexis issued on next quarter's earnings? Codexis issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $152.00 million-$158.00 million, compared to the consensus revenue estimate of $155.49 million. Who are Codexis' key executives? Codexis' management team includes the following people: Mr. John J. Nicols, Pres, CEO & Director (Age 58, Pay $1.33M) (LinkedIn Profile)Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 59, Pay $667.31k)Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & OperationsMs. Asli Aras Ph.D., VP of Corp. Devel.Ms. Karen Frechou-Armijo, Sr. VP & Head of HRDr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of BiotherapeuticsMr. Rob Wilson Ph.D., Sr. VP & GM of Performance EnzymesDr. Stefan Lutz Ph.D., Sr. VP of ResearchMr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & RegulatoryProf. Gerhard N. Mayr, Special Advisor to the Board (Age 76) What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees. Who are some of Codexis' key competitors? Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of CDXS's competitors. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). What is Codexis' stock symbol? Codexis trades on the NASDAQ under the ticker symbol "CDXS." How do I buy shares of Codexis? Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Codexis' stock price today? One share of CDXS stock can currently be purchased for approximately $12.00. How much money does Codexis make? Codexis (NASDAQ:CDXS) has a market capitalization of $783.60 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. How many employees does Codexis have? Codexis employs 261 workers across the globe. How can I contact Codexis? Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for Codexis is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102. This page (NASDAQ:CDXS) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here